Anwar Ahmed

Dr. Anwar Ahmed

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2004 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
AAAnwar Ahmed
Anwar Ahmed
DBDeepak Bararia
Deepak Bararia
SVSumiti Vinayak
Sumiti Vinayak
MYMohammed Yameen
Mohammed Yameen
SBSukla Biswas
Sukla Biswas
YSYagya D. Sharma
Yagya D. Sharma
The combination of sulfadoxine-pyrimethamine (SP) is used as a second line of therapy for the treatment of uncomplicated chloroquine-resistant Plasmodium falciparum malaria. Resistance to SP arises due to certain point mutations in the genes for the dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) enzymes of the parasite. We have analyzed these mutations in 312 field isolates of P. falciparum collected from different parts of India to assess the effects of drug pressure. The rate of mutation in the gene for DHFR was found to be higher than that in the gene for DHPS, although the latter had mutations in more alleles. There was a temporal rise in the number of isolates with double dhfr mutations and single dhps mutations, resulting in an increased total number of mutations in the loci for DHFR and DHPS combined over a 5-year period. During these 5 years, the number of isolates with drug-sensitive genotypes decreased and the number of isolates with drug-resistant genotypes (double DHFR mutations and a single DHPS mutation) increased significantly. The number of isolates with the triple mutations in each of the genes for the two enzymes (for a total of six mutations), however, remained very low, coinciding with the very low rate of SP treatment failure in the country. There was a regional bias in the mutation rate, as isolates from the northeastern region (the state of Assam) showed higher rates of mutation and more complex genotypes than isolates from the other regions. It was concluded that even though SP is prescribed as a second line of treatment in India, the mutations associated with SP resistance continue to be progressively increasing.

1 July 2017 in Journal of Molecular Liquids
Verified
Journal Article
Closed access
MMMohammad Robel Molla
Mohammad Robel Molla
MRMalik Abdul Rub
Malik Abdul Rub
AAAnwar Ahmed
Anwar Ahmed
AHAnamul Hoque
Anamul Hoque

1 January 2016 in Intervirology
Verified
Journal Article
Closed access
IFImam Faizan
Imam Faizan
MAMohd Abdullah
Mohd Abdullah
SASher Ali
Sher Ali
INIrshad H. Naqvi
Irshad H. Naqvi
AAAnwar Ahmed
Anwar Ahmed
SPShama Parveen
Shama Parveen
Zika virus is an arthropod-borne re-emerging pathogen associated with the global pandemic of 2015-2016. The devastating effect of Zika viral infection is reflected by its neurological manifestations such as microcephaly in newborns. This scenario evoked our interest to uncover the neurotropic localization, multiplication of the virus, and the mechanism of microcephaly. The present report provides an overview of a possible molecular mechanism of Zika virus-induced microcephaly based on recent publications. Transplacental transmission of Zika viral infection from mother to foetus during the first trimester of pregnancy results in propagation of the virus in human neural progenitor cells (hNPCs), where entry is facilitated by the receptor (AXL protein) leading to the alteration of signalling and immune pathways in host cells. Further modification of the viral-induced TLR3-mediated immune network in the infected hNPCs affects viral replication. Downregulation of neurogenesis and upregulation of apoptosis in hNPCs leads to cell cycle arrest and death of the developing neurons. In addition, it is likely that the environmental, physiological, immunological, and genetic factors that determine in utero transmission of Zika virus are also involved in neurotropism. Despite the global concern regarding the Zika-mediated epidemic, the precise molecular mechanism of neuropathogenesis remains elusive.

1 October 2017 in Journal of Molecular Liquids
Verified
Journal Article
Closed access
AHAnamul Hoque
Anamul Hoque
MAMasud Alam
Masud Alam
MMMohammad Robel Molla
Mohammad Robel Molla
SRShahed Rana
Shahed Rana
MRMalik Abdul Rub
Malik Abdul Rub
AAAnwar Ahmed
Anwar Ahmed

1 September 2019 in Journal of Molecular Liquids
Verified
Journal Article
Closed access
Naved AzumNaved Azum
Naved Azum
AAAnwar Ahmed
Anwar Ahmed
MRMalik Abdul Rub
Malik Abdul Rub
Abdullah M. AsiriAbdullah M. Asiri
Abdullah M. Asiri
SASalman Freeh Alamery
Salman Freeh Alamery

1 May 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
RRRavikant Ranjan
Ravikant Ranjan
AAAnwar Ahmed
Anwar Ahmed
SGSamudrala Gourinath
Samudrala Gourinath
PSPushkar Sharma
Pushkar Sharma
Recent studies have demonstrated that calcium-dependent protein kinases (CDPKs) are used by calcium to regulate a variety of biological processes in the malaria parasite Plasmodium. CDPK4 has emerged as an important enzyme for parasite development, because its gene disruption in rodent parasite Plasmodium berghei causes major defects in sexual differentiation of the parasite ( Billker, O., Dechamps, S., Tewari, R., Wenig, G., Franke-Fayard, B., and Brinkmann, V. (2004) Cell 117, 503-514 ). Despite these findings, it is not very clear how PfCDPK4 or any other PfCDPK is regulated by calcium at the molecular level. We report the biochemical characterization and elucidation of molecular mechanisms involved in the regulation of PfCDPK4. PfCDPK4 was detected on gametocyte periphery, and its activity in the parasite was regulated by phospholipase C. Even though the Junction Domain (JD) of PfCDPK4 shares moderate sequence homology with that of the plant CDPKs, it plays a pivotal role in PfCDPK4 regulation as previously reported for some plant CDPKs. The regions of the J-domain involved in interaction with both the kinase domain and the calmodulin-like domain were mapped. We propose a model for PfCDPK regulation by calcium, which may also prove useful for design of inhibitors against PfCDPK4 and other members of the PfCDPK family.